Women with non-small cell lung cancers live longer than men
Women with non-small cell lung cancers live longer than men

Source: Loyola University Health System


Non-small cell lung cancer: women live longer than men

Women diagnosed with non-small cell lung cancers (NSCLC) live longer than their male counterparts, according to results of a SWOG study presented by Loyola Medicine researcher Kathy Albain, MD, at the International Association for the Study of Lung Cancer's 19th World Conference on Lung Cancer in Toronto.

Dr. Albain led the international study, S0424, for SWOG, the cancer clinical trials group that is part of the National Cancer Institute's National Clinical Trials Network, the nation's oldest and largest publicly-funded cancer research network. Dr. Albain and her SWOG team studied 981 patients newly diagnosed with stage I, II or III NSCLC. Non-small cell lung cancers account for about 80 to 85 percent of all lung cancers.

Researchers grouped patients into four groups based on sex and smoking history. Then, they analyzed data on cancer stage, patients' tumor type and mutations, hormonal influences, treatment plans and survival rates. Patients were followed for five years, or until their deaths, in order to determine overall survival, or how long they lived after enrolling in the trial.

Prospective trial

The study is the first prospective trial of this scope for NSCLC, designed specifically to follow survival outcomes. It represents collaboration across the clinical trials network, and included researchers from Canada and Japan.

Regardless of smoking history or any other factor, women in S0424 had significantly better overall survival (OS) rates compared to men. The analysis found that female never-smokers (FNS) and female ever-smokers (FES) had significantly better OS compared to male never-smokers (MNS) and male ever-smokers (MES). Five-year estimates reported overall survival at 73 percent for FNS, 69 percent for FES, 58 percent for MNS and 52 percent for MES. Women lived longer, even when adjustments were made for the medical care they received, their smoking history, hormonal factors, or the presence of mutations in their tumors common to NSCLC types.

"Females with NSCLC survive better, even when we control for every factor that might influence survival in NSCLC, including tobacco and other exposures, lifestyle factors, disease stage, treatment, tumor biology and hormonal factors," Dr. Albain said. "Additional study is needed to further investigate favorable female survival in this population and our large clinical trials need to be equally balanced for females."

Source: Loyola University Health System


Read all latest stories

Related articles

Precancerous lesions

Lung cancer: early detection with molecular profiling

Before lung cancer develops, precancerous lesions are found in the airway, but only half of these will actually become lung cancer, while others will disappear or remain benign without becoming…

Man against machine

AI is better than dermatologists at diagnosing skin cancer

Researchers have shown for the first time that a form of artificial intelligence or machine learning known as a deep learning convolutional neural network (CNN) is better than experienced…


Benefits from The Cancer Genome Atlas

Last year, scientists at the University of California San Francisco (UCSF) revealed that by measuring the proportion of both immune and cancerous cells in tumours, or ‘tumour purity,’ clinicians…

Related products

Research use only (RUO)

Eppendorf - Mastercycler nexus X2

Eppendorf AG

Research use only (RUO)

SARSTEDT - Low DNA Binding Micro Tubes


Research use only (RUO)

Shimadzu - CLAM-2000

Shimadzu Europa GmbH

Oncology MR

Siemens Healthineers - MAGNETOM RT Pro edition

Siemens Healthineers